Manila Times Business
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026. "As a leader in rare endocrine diseases, we are committed to sharing comprehensive clin
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
FireFly Metals Announces OTC Markets Ticker Symbol Change to FFMFF
1h ago
Former ICC chief prosecutor in Duterte case suspended amid sex abuse claims
1h ago
Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel
1h ago
GoldHaven Confirms LIFE Offering Terms
1h ago